High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Nat Med · 2026 · PMC13004686 · PMID 41634391

Europe PMC DOI

hedged sentence

0.0075

closest p · 0.1× alpha

0.0075

boldest claim

The sentences

nominally significantP = 0.0075actually significant

More rapid reductions in NfL levels were observed in the 50/28 mg group (88%) compared with the 12/12 mg group (77%) at day 64 (nominally significant P = 0.0075; joint-rank test) (Fig. 2b ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.